Thrombolysis in Myocardial Infarction (TIMI)

• Status: Completed
• Trial end date: 1990-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In TIMI I, to assess the relative thrombolytic activity and side effects of intravenous recombinant tissue-type plasminogen activator (rt-PA) versus intravenous streptokinase in patients with acute myocardial infarction. In TIMI II, to assess whether intravenous rt-PA given in the early hours of acute myocardial infarction should be followed by percutaneous transluminal coronary angioplasty (PTCA).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Plasminogen; Tissue Plasminogen Activator

Criteria

Men and women under age 76. Patients had acute myocardial infarction.